FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class ...
MarketWatch1mon
Novartis says FDA gives accelerated approval for kidney-disease treatment
The approval follows a Phase 3 study in which the treatment, Fabhalta, achieved a 44% reduction in this elevated protein level, called proteinuria, at nine months relative to baseline in patients ...
GlobalData on MSN1mon
US FDA approves Novartis’ Fabhalta in IgAN treatment
Novartis has secured US Food and Drug Administration (FDA) accelerated approval for Fabhalta (iptacopan) for reducing ...
Buy Rating Affirmed: Novartis AG’s Strong Growth Outlook and Underestimated Pipeline Potential
In a report released yesterday, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...
Wall Street Journal18d
Health Care Roundup: Market Talk
Jefferies is more bullish than consensus estimates on Novartis’s longer-term growth trajectory due to optimism in the new launches of its Scemblix, Pluvicto & Fabhalta drugs, the analysts add.
The Globe and Mail1mon
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
Novartis will focus exclusively on developing brand-new drugs from now on. Some of its newer approvals include Fabhalta, a therapy for paroxysmal nocturnal hemoglobinuria (a rare blood disorder ...
National Institute for Health and Care Excellence17d
Iptacopan for treating paroxysmal nocturnal haemoglobinuria
Iptacopan (Fabhalta) is available on the NHS. It is a possible treatment for paroxysmal nocturnal haemoglobinuria in adults with haemolytic anaemia. Your healthcare professionals should give you clear ...
FiercePharma16d
Despite trial scare, Travere's Filspari gains full FDA nod in kidney disease showdown with Novartis
Then the FDA in August handed Novartis’ complement inhibitor Fabhalta an accelerated approval. The Swiss pharma’s selective ETA receptor inhibitor, atrasentan, is also under FDA review.
Pharmabiz1mon
Novartis receives US FDA accelerated approval for Fabhalta, the first and only complement inhibitor for reduction of proteinuria in primary IgAN
Novartis announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in ...
pharmaphorum17d
Novartis' oral PNH drug Fabhalta rolls out in England, Wales
Fabhalta (iptacopan) was approved by UK drugs regulator the MHRA last month, becoming an option for an estimated 220 out of ...
pharmaphorum9mon
Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH
Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The drug ...